You are here:
Several research groups at Helmholtz Munich are working on innovative vaccines. Two of them are about to clear a crucial hurdle before approval - fighting the Epstein-Barr virus and Hepatitis B. But how do researchers develop a vaccine?
EU Project PerForM-REACT Strengthens Pandemic Preparedness Efforts
On March 11, 2024, the inauguration of the expanded safety laboratory in Augsburg marked a milestone within the EU-funded "PerForM-REACT" project, aimed at enhancing pandemic…
Epigenetic changes play important roles in cancer, metabolic and aging-related diseases, but also during loss of resilience as they cause the genetic material to be incorrectly interpreted in affected cells. A major study by scientists at Helmholtz…
TherVacB, a novel therapeutic vaccine to combat chronic hepatitis B, entered the first clinical trial. The vaccine was designed and developed under the leadership of Helmholtz Munich. This phase 1a clinical trial is conducted at the Division of…
A precursor of cholesterol, previously categorised as harmful, can protect cancer cells from cell death. This finding, published in Nature, opens new doors for cancer research.
Epstein-Barr Virus (EBV) is widespread and very contagious: according to the World Health Association more than 90 percent of the global population are infected with this virus throughout their lives. The virus causes B and T cell lymphomas (cancer…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:
